Health Care [ 9/12 ] | Biotechnology [ 53/74 ]
NASDAQ | Common Stock
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs.
Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.
The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB.
FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 6, 24 | -0.16 Increased by +82.22% | -0.32 Increased by +50.00% |
| May 6, 24 | -0.33 Increased by +59.26% | -0.42 Increased by +21.43% |
| Feb 26, 24 | -0.57 Increased by +18.57% | -0.42 Decreased by -35.71% |
| Nov 6, 23 | -0.52 Increased by +46.94% | -0.68 Increased by +23.53% |
| Aug 7, 23 | -0.90 Decreased by -15.38% | -0.70 Decreased by -28.57% |
| May 8, 23 | -0.81 Decreased by -19.12% | -0.75 Decreased by -8.00% |
| Feb 27, 23 | -0.70 Increased by +51.72% | -0.94 Increased by +25.53% |
| Nov 7, 22 | -0.98 Decreased by -281.48% | -0.81 Decreased by -20.99% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 24 | 50.64 M Increased by +14.26% | -15.54 M Increased by +82.27% | Decreased by -30.69% Increased by +84.49% |
| Mar 31, 24 | 55.90 M Increased by +54.59% | -32.93 M Increased by +57.51% | Decreased by -58.91% Increased by +72.51% |
| Dec 31, 23 | 27.14 M Decreased by -21.03% | -56.23 M Increased by +15.38% | Decreased by -207.21% Decreased by -7.16% |
| Sep 30, 23 | 40.13 M Increased by +155.06% | -63.62 M Increased by +30.90% | Decreased by -158.51% Increased by +72.91% |
| Jun 30, 23 | 44.32 M Increased by +48.69% | -87.68 M Decreased by -19.80% | Decreased by -197.84% Increased by +19.43% |
| Mar 31, 23 | 36.16 M Decreased by -40.55% | -77.50 M Decreased by -22.00% | Decreased by -214.32% Decreased by -105.22% |
| Dec 31, 22 | 34.37 M Increased by +107.74% | -66.45 M Increased by +50.44% | Decreased by -193.37% Increased by +76.14% |
| Sep 30, 22 | 15.73 M Decreased by -89.91% | -92.06 M Decreased by -284.86% | Decreased by -585.05% Decreased by -1.93 K% |